ArticleMolecular cancer therapeutics2019

Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.

Sudan N Loganathan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.